arrow
N

Nicoletta Cordani

Department of Medicine and Surgery
H指数:17
被引数:1,056

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer

作者更正:对3600多种肿瘤中KEAP1/NFE2L2变异的整合分析揭示了NRF2表达谱是一种癌症预后生物标志物

2025-09-160
OAAI
A Phase 2, Open Label, Multicenter, Single Arm Trial Evaluating the Activity and Safety of Abemaciclib + Aromatase Inhibitors (AIs) as Second-Line Treatment After First-Line Fulvestrant in Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-Factor-Receptor-Negative (HER2-) Metastatic Breast Cancer (MBC) Patients. Final Results of HERMIONE-7 Trial

一项评估阿贝西利联合芳香化酶抑制剂(AIs)作为一线氟维司群后二线治疗的活性与安全性的2期、开放标签、多中心、单臂试验,适用于激素受体阳性(HR+)、人表皮生长因子受体阴性(HER2-)转移性乳腺癌(MBC)患者。HERMIONE-7试验的最终结果。

2025-05-130
PRE
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma
2024-10-300
OAAI
BASELINE 18FDG-PET METABOLIC TUMOUR VOLUME (MTV) AS A POTENTIAL PREDICTIVE FACTOR OF RESPONSE TO METRONOMIC CHEMOTHERAPY (mCHT) IN HR+/HER2-METASTATIC BREAST CANCER (MBC) PATIENTS (pts). PRELIMINARY RESULTS OF THE METRO-PET STUDY
2023-03-010
PRE
Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation
2022-11-307
OAAI